4.6 Article

5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 19, Issue 34, Pages 5665-5670

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v19.i34.5665

Keywords

5-aminosalicylic acid; Inflammatory bowel diseases; Mucosal concentration

Ask authors/readers for more resources

AIM: To compare the mucosal concentrations of 5-aminosalicylic acid (5-ASA) resulting from different pharmaceutical formulations and analyse the influence of inflammation on the mucosal concentrations. METHODS: The study included 130 inflammatory bowel disease (IBD) patients receiving 5-ASA as pH-dependent-release formulations (73 patients), time-dependent-release formulations (11 patients), or pro-drugs (18 patients). In addition, 28 patients were receiving topical treatment (2-4 g/d) with pH-dependent-release formulations. Endoscopic biopsies were obtained from the sigmoid region during the colonoscopy. The 5-ASA concentrations (ng/mg) were measured in tissue homogenates using high-pressure liquid chromatography with electro-chemical detection. The t test and Mann-Whitney test, when appropriate, were used for statistical analysis. RESULTS: Patients receiving pH-dependent-release formulations showed significantly higher mucosal concentrations of 5-ASA (51.75 +/- 5.72 ng/mg) compared with patients receiving pro-drugs (33.35 +/- 5.78 ng/mg, P = 0.01) or time-dependent-release formulations (38.24 +/- 5.53 ng/mg, P = 0.04). Patients with endoscopic remission had significantly higher mucosal concentrations of 5-ASA than patients with active disease (60.14 +/- 7.95 ng/mg vs 35.66 +/- 5.68 ng/mg, P = 0.02). Similar results were obtained when we compared patients with the histological appearance of remission and patients with active histological inflammation (67.53 +/- 9.22 ng/mg vs 35.53 +/- 5.63 ng/mg, P < 0.001). Significantly higher mucosal concentrations of 5-ASA were detected in patients treated with both oral and topical treatments in combination compared with patients who received oral treatment with pH-dependent-release formulations alone (72.33 +/- 11.23 ng/mg vs 51.75 +/- 5.72 ng/mg, P = 0.03). CONCLUSION: IBD patients showed significant variability in mucosal 5-ASA concentrations depending on the type of formulation, and the highest mean concentration was achieved using pH-dependent-release formulations. (C) 2013 Baishideng. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available